http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1377312-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2bd5a4d4394798ebf7dc1fbb05f81128 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-166 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 |
| filingDate | 2002-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c77b15ad63213090ef3afa567b982fd2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce424496aa8aa188dc9ec5e849b46d09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cec3f396901f9a99959eb1d7fad0fa3 |
| publicationDate | 2004-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1377312-A1 |
| titleOfInvention | Anthrax lethal factor inhibits tumor growth and angiogenesis |
| abstract | A method for inhibiting cell angiogenesis comprises contacting cells associated with undesired angiogenesis with an effective amount of an inhibitor of MEK or of an enzyme that is a member of the MAPK family. MEK inhibitors include MEK-directed proteases such as Bacillus anthracis lethal factor or a functional derivative thereof. Organic small molecule inhibitors of MEK include PD98059, U0126 and PD184352. The above contacting may be performed in vivo, in a human or other mammalian subject. Also included is a method to treat a mammalian subject having a disease or condition associated with undesired angiogenesis or neovascularization, comprising administering to the subject an effective amount of a pharmaceutical composition that comprises an inhibitor of MEK or of an enzyme that is a member of the MAPK family, as noted above, and pharmaceutically acceptable carrier or excipient. The treatment method is useful for a disease or condition such as tumor growth, tumor invasion or tumor metastasis, wherein the angiogenesis inhibition results in reduction in size or growth rate of the tumor or its destruction. |
| priorityDate | 2001-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 207.